Sendai virus, an RNA virus with no risk of genomic integration, delivers CRISPR/Cas9 for efficient gene editing
A significant recent advance in genome engineering is the development of the CRISPR/Cas9 system for nuclease based genome editing. However, several cell types are not easily transfected and in vivo delivery of the CRISPR system remains challenging. To enhance delivery efficiency, one solution is use of viral vectors such as lentiviral or adeno-associated viral systems. However, these viral vectors have the potential for undesired random integration into the host genome.
In this study, the scientists repurpose Sendai virus, an RNA virus with no viral DNA phase as a delivery system for efficient Cas9-mediated gene editing. The high efficiency of Sendai virus infection resulted in high rates of on-target mutagenesis in cell lines (75–98% at various endogenous and transgenic loci) and primary human monocytes (88% at the ccr5 locus) in the absence of any selection. In conjunction with extensive former work on Sendai virus as a promising gene therapy vector that can infect a wide range of cell types including hematopoietic stem cells, this proof-of-concept study opens the door to using Sendai virus as well as other RNA viral vectors as versatile and efficient tools for gene editing.
GEG Tech develops several lines of vectors based on lentivirus and offers to include CRISPR system within. For the moment, GEG Tech provides the CRISPR system into integrating lentiviral vectors and non-integrating lentiviral vectors which already offer a wide range of applications. The R&D team is working to include the CRISPR system in the specific line of vectors only developed by GEG Tech which is RNA lentiviral vector. In this way, the CRISPR system may benefit to the advantage of the lentiviral vector technology: efficiency, cell/tissue specificity, high cargo capacity and low immunogenicity while being expressed transiently and having high level of biosafety. We look forward to offering you this type of vector!